Carl L. Gordon - 04 Jun 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Director
Issuer ticker: KROS
Reported as of: 04 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 16:15:19 UTC
Prior SEC filing: 11 Apr 2025
Next SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Keith Regnante, Attorney-in-Fact

Key filing fact

Carl L. Gordon filed Form 4 for Keros Therapeutics, Inc. (KROS) on 06 Jun 2025.

Key facts

This page summarizes Carl L. Gordon's Form 4 filing for Keros Therapeutics, Inc. (KROS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 16:15.

Change

Previous filing in this sequence was filed on 11 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001282930 Primary reporting owner

GORDON CARL L

Relationship: Director
Address: C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON
Signature: /s/ Keith Regnante, Attorney-in-Fact
Signature date: 06 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KROS transaction

Common Stock

Award

Transaction value: $0
Shares: +5,250
Change %
Price: $0.000000
Shares after: 5,250
Date: 04 Jun 2025
Ownership: Direct
Footnotes: F1, F2

KROS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 899,212
Date: 04 Jun 2025
Ownership: See footnotes
Footnotes: F3, F4

KROS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 119,522
Date: 04 Jun 2025
Ownership: See footnotes
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KROS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +10,500
Change %
Price: $0.000000
Shares after: 10,500
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,500
Exercise price: $14.82
Footnotes: F2, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.

Footnote F3

These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.

Footnote F4

Each of the Reporting Person, OrbiMed Advisors, OrbiMed GP, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Footnote F5

. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.

Footnote F6

The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.